Scholars Central

Conference abstractPublished 7 Oct 2022

Soluble Urokinase Receptor as a promising marker for early prediction of outcome in COVID-19 hospitalized patients

Authors: Filomena Napolitano

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to become a global pandemic, putting a strain on health care systems. SARS-CoV-2 infection may be associated with mild symptoms or, in severe cases, lead patients to intensive care unit (ICU) or death. The critically ill patients suffer from acute respiratory distress syndrome (ARDS), sepsis, thrombotic complications and multiple organ failure. For optimization of hospital resources, several molecular markers have been evaluated in order to stratify COVID-19 patients, based on the risk of developing a mild or severe disease. More recently, soluble urokinase receptor (suPAR) has attracted scientific interest because it seems to discriminate better than some other biomarkers among patients with different severities of illness. We investigated the newly introduced inflammatory marker suPAR in hospitalized patients affected by different forms of COVID-19, from mild to severe disease or death. In a wide population of acute medical patients, suPAR is strongly associated with disease severity and mortality, suggesting that suPAR could be used in the clinic as a prognostic indicator. Recent Publications : 1. D'Alonzo, D.; De Fenza, M.; Pavone, V. COVID-19 and pneumonia: a role for the uPA/uPAR system. Drug Discov Today 2020, 25, 1528-1534. 2. Rovina, N.; Akinosoglou, K.; Eugen-Olsen, J.; Hayek, S.; Reiser, J.; GiamarellosBourboulis, E.J. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 2020, 24, 187. 3. Chalkias, A.; Mouzarou, A.; Samara, E.; Xanthos, T.; Ischaki, E., Pantazopoulos, I. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Mol Diagn Ther

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Immune Disorders & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Immune Disorders & Therapy
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Filomena Napolitano”